Search Results

27 posts

Botannix Pharmaceuticals’ resubmission of Sofdra NDA accepted by FDA

Botannix Pharmaceuticals' (ASX:BOT) resubmission of the new drug application for Sofdra has been accepted by the…

Botanix Pharmaceuticals completes HF validation study for Sofdra, eyes FDA approval by mid-2024

Botanix Pharmaceuticals (ASX:BOT) has completed the planned human factors (HF) validation study for Sofdra, evaluating revised…

FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to…

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

Botanix Pharmaceuticals (ASX:BOT) suffers setback in FDA approval for sofpironium bromide gel to treat hyperhidrosis

Botanix Pharmaceuticals (ASX:BOT) has had its application to use the novel sofpironium bromide gel to treat…
Botanix Pharmaceuticals (ASX:BOT) - Incoming CEO, Dr Howie McKibbon

Botanix Pharmaceuticals (ASX:BOT) appoints Dr Howie McKibbon as CEO

Botanix Pharmaceuticals (ASX:BOT) has appointed Dr Howie McKibbon as its newest Chief Executive Officer, effective from…

Botanix Pharmaceuticals (ASX:BOT) completes $12.5m placement and royalty buyout

Botanix Pharmaceuticals (ASX:BOT) has completed a $12.5 million placement and executed a buyout agreement for milestones…
Botanix Pharmaceuticals (ASX:BOT) - Executive Chair, Vince Ippolito

Botanix Pharmaceuticals (ASX:BOT) raises $12.5m to extinguish future milestone and royalty payments

Botanix Pharmaceuticals (ASX:BOT) has secured firm commitments to raise $12.5 million via an institutional placement.

Botanix Pharmaceuticals (ASX:BOT) passes FDA mid-cycle review for Sofpironium Bromide

Botanix Pharmaceuticals' (ASX:BOT) lead product, Sofpironium Bromide, had passed a US Food and Drug Administration (FDA)…
The Market Online Video

Botanix Pharmaceuticals (ASX:BOT) confirms US FDA NDA application formally under review

Botanix Pharmaceuticals (ASX:BOT) has received confirmation from the US Food and Drug Administration (FDA) that its…
The Market Online Video

Botanix Pharmaceuticals (ASX:BOT) placement and SPP raises just shy of $6m

Botanix Pharmaceuticals (ASX:BOT) has raised $5.96 million through a placement and share purchase plan (SPP) to…
The Market Online Video

Botanix Pharmaceuticals (ASX:BOT) launches $8m capital raise

Botanix Pharmaceuticals (ASX:BOT) is set to raise $8 million through a private placement and a share…
Botanix Pharmaceuticals (ASX:BOT) - Incoming CEO, Dr Howie McKibbon

Botanix Pharmaceuticals (ASX:BOT) promotes Dr McKibbon to COO

Botanix Pharmaceuticals' (ASX:BOT) Chief Commercial Officer, Dr Howie McKibbon has been promoted to Chief Operating Officer.
The Market Online Video

Botanix Pharmaceuticals (ASX:BOT) returns positive rosacea study results

Botanix Pharmaceuticals (ASX:BOT) has received positive data from its phase 1b/2 papulopustular rosacea clinical study.
The Market Online Video

Botanix Pharmaceuticals (ASX:BOT) submits new FDA application for sofpironium bromide

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has submitted a new drug application (NDA) to the FDA…
The Market Online Video

Botanix Pharmaceuticals (ASX:BOT) to raise $7.5m for sofpironium bromide FDA filing

Botanix Pharmaceuticals (ASX:BOT) has tapped investors for $7.5 million via a share placement.
The Market Online Video

Botanix Pharmaceuticals (ASX:BOT) accelerates Sofpironium Bromide NDA filing

Botanix Pharmaceuticals (ASX:BOT) has accelerated the submission of a New Drug Approval (NDA) for its Sofpironium…
Botanix Pharmaceuticals (ASX:BOT) - Executive Chair, Vince Ippolito

Botanix Pharmaceuticals (ASX:BOT) acquires new dermatology asset

Botanix Pharmaceuticals (BOT) acquires Sofpironium Bromide gel from NASDAQ listed company Brickell Biotech.
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

Botanix Pharmaceuticals (ASX:BOT) granted FDA new infectious disease designation status

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has been granted Qualified Infectious Disease Product (QIDP) status.

Botanix Pharmaceuticals (ASX:BOT) spends $4.1 million on R&D program

Botanix Pharmaceuticals Limited (ASX:BOT) shares its half yearly report and highlights its dermatology program advancements.